Pap Test Use and Cervical Cancer Incidence in First Nations Women Living in Manitoba
Pap Test Use and Cervical Cancer Incidence in First Nations Women Living in Manitoba
复制标题
DOI：
10.1158/1940-6207.capr-14-0277
复制
发表时间：
2015-01-01
影响因子：
3.3
通讯作者：
Turner, Donna
中科院分区：
文献类型：
--
作者：
Decker, Kathleen M.;Demers, Alain A.;Turner, Donna
本研究探讨巴氏（巴氏）试验的利用，巴氏试验结果，和宫颈癌的发病率之间的第一民族（FN）妇女生活在加拿大马尼托巴考虑到年龄组，时间段和居住区。六个基于人口的数据来源在个人层面上相互关联。采用负二项回归比较FN和所有其他马尼托巴（AOM）妇女之间的巴氏试验利用率和结果。Poisson回归用于比较宫颈癌发病率。在25岁以下的女性中，FN比AOM女性更有可能进行巴氏试验[率比（RR）= 1.37，95%置信区间（CI），1.22-1.53，18-19奥尔兹; RR = 1.17，95% CI，1.05-1.31，20-24奥尔兹]。25至29岁或30至39岁的女性使用巴氏试验没有差异。40岁及以上的FN比AOM女性更不可能进行巴氏试验（RR = 0.84，95% CI，0.75-0.93，40-49岁; RR = 0.71，95% CI，0.63-0.79，50-59岁; RR = 0.59，95% CI，0.52-0.66，60-69岁）。FN比AOM妇女更可能有高（RR = 1.88，95% CI，1.65-2.13）或低级别的巴氏试验结果（RR = 1.60，95% CI，1.48-1.73）。25至39岁FN妇女的浸润性宫颈癌发病率是40至69岁妇女的两倍（21.9/100，000，FN; 10.2/100，000，AOM，P = 0.006）和（24.3/100，000，FN; 12.3/100，000，AOM，P = 0.007）。总之，必须增加40岁以上新生力量妇女的宫颈癌筛查，以解决宫颈癌发病率较高的问题。(C)2014年AACR。
This study examined Papanicolaou (Pap) test utilization, Pap test results, and cervical cancer incidence among First Nations (FN) women living in Manitoba, Canada taking into account age group, time period, and area of residence. Six population-based data sources were linked at an individual level. Negative binomial regression was used to compare Pap test utilization and results between FN and all other Manitoba (AOM) women. Poisson regression was used to compare cervical cancer incidence. Among women younger than 25 years, FN were more likely than AOM women to have had a Pap test [rate ratio (RR) = 1.37, 95% confidence intervals (CI), 1.22-1.53, 18-19 year olds; RR = 1.17, 95% CI, 1.05-1.31, 20-24 year olds]. There was no difference in Pap test use for women 25 to 29 or 30 to 39 years. FN 40 years and older were less likely to have a Pap test than AOM women (RR = 0.84, 95% CI, 0.75-0.93, 40-49 years old; RR = 0.71, 95% CI, 0.63-0.79, 50-59 years old; RR = 0.59, 95% CI, 0.52-0.66, 60-69 years old). FN were more likely than AOM women to have a high (RR = 1.88, 95% CI, 1.65-2.13) or low-grade Pap test result (RR = 1.60, 95% CI, 1.48-1.73). The invasive cervical cancer incidence rate was double for FN women 25 to 39 years of age (21.9 per 100,000, FN; 10.2 per 100,000, AOM, P = 0.006) and 40 to 69 years of age (24.3 per 100,000, FN; 12.3 per 100,000, AOM, P = 0.007). In conclusion, cervical cancer screening among FN women over 40 years of age must be increased to address the higher cervical cancer incidence. (C) 2014 AACR.